Besifovir(b)

CAS No. 441785-25-7

Besifovir(b)( —— )

Catalog No. M20442 CAS No. 441785-25-7

Besifovir a parent drug converted by LB80380 further metabolizes to its active form LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 122 In Stock
5MG 128 In Stock
10MG 187 In Stock
25MG 312 In Stock
50MG 454 In Stock
100MG 663 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Besifovir(b)
  • Note
    Research use only, not for human use.
  • Brief Description
    Besifovir a parent drug converted by LB80380 further metabolizes to its active form LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV).
  • Description
    Besifovir a parent drug converted by LB80380 further metabolizes to its active form LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    441785-25-7
  • Formula Weight
    299.22
  • Molecular Formula
    C10H14N5O4P
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL?(835.51 mM)
  • SMILES
    Nc1ncc2ncn(CC3(CC3)OCP(O)(O)=O)c2n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Mak L Y Seto W K Lai C L et al. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection[J]. Expert Opinion on Drug Metabolism & Toxicology 2018 14(1):101-106.
molnova catalog
related products
  • HEC72702

    HEC72702 is a novel potent, orally active inhibitor of HBV capsid assembly, inhibits HBV-DNA levels in HepG.2.2.15 cells with IC50 of 39 nM.

  • Bay 41-4109 racemate

    The racemate form of Bay 41-4109, which is a potent, non-nucleosidic inhibitor of HBV nucleocapsid maturation with IC50 of 0.05 uM.

  • Lagociclovir

    Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.